1. GBD 2016 Neurology Collaborators . Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480. doi:10.1016/S1474-4422(18)30499-X
Google Scholar | Crossref | Medline2. Marras, C, Beck, JC, Bower, JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21. doi:10.1038/s41531-018-0058-0
Google Scholar | Crossref | Medline3. Van Den Eeden, SK, Tanner, CM, Bernstein, AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022. doi:10.1093/aje/kwg068
Google Scholar | Crossref | Medline | ISI4. Postuma, RB, Berg, D, Stern, M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424
Google Scholar | Crossref | Medline5. Ffytche, DH, Pereira, JB, Ballard, C, Chaudhuri, KR, Weintraub, D, Aarsland, D. Risk factors for early psychosis in PD: insights from the Parkinson’s progression markers initiative. J Neurol Neurosurg Psychiatry. 2017;88(4):325–331. doi:10.1136/jnnp-2016-314832
Google Scholar | Crossref | Medline6. Rothenberg, KG, Rajaram, R. Advances in management of psychosis in neurodegenerative diseases. Curr Treat Options Neurol. 2019;21(1):3. Published 2019 Jan 23. doi:10.1007/s11940-019-0545-6
Google Scholar | Crossref | Medline7. Fénelon, G, Alves, G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1-2):12–17. doi:10.1016/j.jns.2009.08.014
Google Scholar | Crossref | Medline8. Taddei, RN, Cankaya, S, Dhaliwal, S, Chaudhuri, KR. Management of psychosis in Parkinson’s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017. doi:10.1155/2017/3256542
Google Scholar | Medline9. Chaudhuri, KR, Healy, DG, Schapira, AH; National Institute for Clinical Excellence . Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245. doi:10.1016/S1474-4422(06)70373-8
Google Scholar | Crossref | Medline | ISI10. Fénelon, G, Mahieux, F, Huon, R, Ziégler, M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123 (Pt 4):733–745. doi:10.1093/brain/123.4.733
Google Scholar | Crossref | Medline | ISI11. Factor, SA, Feustel, PJ, Friedman, JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003;60(11):1756–1761. doi:10.1212/01.wnl.0000068010.82167.cf
Google Scholar | Crossref | Medline12. Pappert, EJ, Goetz, CG, Niederman, FG, Raman, R, Leurgans, S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord. 1999;14(1):117–121. doi:10.1002/1531-8257(199901)14:1<117:: aid-mds1019>3.0.co;2-0
Google Scholar | Crossref | Medline | ISI13. Samudra, N, Patel, N, Womack, KB, Khemani, P, Chitnis, S. Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging. 2016;33(12):855–863. doi:10.1007/s40266-016-0416-8
Google Scholar | Crossref | Medline14. Barnes, J, David, AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727–733. doi:10.1136/jnnp.70.6.727
Google Scholar | Crossref | Medline | ISI15. Schneider, RB, Iourinets, J, Richard, IH. Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017;7(6):365–376. doi:10.2217/nmt-2017-0028
Google Scholar | Crossref | Medline16. Thanvi, BR, Lo, TC, Harsh, DP. Psychosis in Parkinson’s disease. Postgrad Med J. 2005;81(960):644–646. doi:10.1136/pgmj.2004.032029
Google Scholar | Crossref | Medline17. Lenka, A, Pagonabarraga, J, Pal, PK, Bejr-Kasem, H, Kulisvesky, J. Minor hallucinations in Parkinson disease: a subtle symptom with major clinical implications [published correction appears in Neurology. 2019 Oct 15;93(16):725]. Neurology. 2019;93(6):259–266. doi:10.1212/WNL.0000000000007913
Google Scholar | Crossref | Medline18. Amar, BR, Yadav, R, Janardhan Reddy, YC, Pal, PK. A clinical profile of patients with Parkinson’s disease and psychosis. Ann Indian Acad Neurol. 2014;17(2):187–192. doi:10.4103/0972-2327.132625
Google Scholar | Crossref | Medline19. Ropacki, SA, Jeste, DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022–2030. doi:10.1176/appi.ajp.162.11.2022
Google Scholar | Crossref | Medline | ISI20. Hall, D, Finger, EC. Psychotic symptoms in frontotemporal dementia. Curr Neurol Neurosci Rep. 2015;15(7):46. doi:10.1007/s11910-015-0567-8
Google Scholar | Crossref | Medline21. Gossink, FT, Vijverberg, EG, Krudop, W, et al. Psychosis in behavioral variant frontotemporal dementia. Neuropsychiatr Dis Treat. 2017;13:1099–1106. doi:10.2147/NDT.S127863
Google Scholar | Crossref | Medline22. Aarsland, D, Ballard, C, Larsen, JP, McKeith, I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528–536. doi:10.1002/gps.389
Google Scholar | Crossref | Medline23. Weintraub, D, Hurtig, HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491–1498. doi:10.1176/appi.ajp.2007.07040715
Google Scholar | Crossref | Medline | ISI24. Wolters, EC . Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology. 1999;52(7 suppl 3): S10–S13.
Google Scholar | Medline25. Stahl, SM . Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016;21(5):355–359. doi:10.1017/S1092852916000602
Google Scholar | Crossref | Medline26. Harding, AJ, Broe, GA, Halliday, GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391–403. doi:10.1093/brain/awf033
Google Scholar | Crossref | Medline | ISI27. Zahodne, LB, Fernandez, HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682. doi:10.2165/00002512-200825080-00004
Google Scholar | Crossref | Medline | ISI28. Riederer, P, Lange, KW, Kornhuber, J, Danielczyk, W. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung. 1992;42(2A):265–268.
Google Scholar | Medline29. Rodríguez-Violante, M, Cervantes-Arriaga, A, González-Latapí, P, León-Ortiz, P, de la Fuente-Sandoval, C, Corona, T. Proton magnetic resonance spectroscopy changes in Parkinson’s disease with and without psychosis. Rev Invest Clin. 2015;67(4):227–234.
Google Scholar | Medline30. West, AR, Floresco, SB, Charara, A, Rosenkranz, JA, Grace, AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003;1003:53–74. doi:10.1196/annals.1300.004
Google Scholar | Crossref | Medline | ISI31. Lenka, A, Ingalhalikar, M, Shah, A, et al. Hippocampal subfield atrophy in patients with Parkinson’s disease and psychosis. J Neural Transm (Vienna). 2018;125(9):1361–1372. doi:10.1007/s00702-018-1891-3
Google Scholar | Crossref | Medline32. Lenka, A, Ingalhalikar, M, Shah, A, et al. Abnormalities in the white matter tracts in patients with Parkinson disease and psychosis. Neurology. 2020;94(18):e1876–e1884. doi:10.1212/WNL.0000000000009363
Google Scholar | Crossref | Medline33. Ravina, B, Marder, K, Fernandez, HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH Work Group. Mov Disord. 2007;22(8):1061–1068. doi:10.1002/mds.21382
Google Scholar | Crossref | Medline | ISI34. Fernandez, HH, Aarsland, D, Fénelon, G, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(4):484–500. doi:10.1002/mds.21875
Google Scholar | Crossref | Medline | ISI35. Levin, J, Hasan, A, Höglinger, GU. Psychosis in Parkinson’s disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45–50. doi:10.1007/s00702-015-1400-x
Google Scholar | Crossref | Medline36. Wand, AP, Peisah, C. Managing psychosis in Parkinson’s disease without drugs. Neurodegener Dis Manag. 2015;5(4):271–274. doi:10.2217/nmt.15.27
Google Scholar | Crossref | Medline37. Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3(03):S42–S80. doi:10.1002/mds.23884
Google Scholar | Crossref | Medline38. Parkinson Study Group . Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–763. doi:10.1056/NEJM199903113401003
Google Scholar | Crossref | Medline39. Bozymski, KM, Lowe, DK, Pasternak, KM, Gatesman, TL, Crouse, EL. Pimavanserin: a novel antipsychotic for Parkinson’s disease psychosis. Ann Pharmacother. 2017;51(6):479–487. doi:10.1177/1060028017693029
Google Scholar | SAGE Journals | ISI40. Desmarais, P, Massoud, F, Filion, J, Nguyen, QD, Bajsarowicz, P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227–236. doi:10.1177/0891988716640378
Google Scholar | SAGE Journals | ISI41. Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318. doi:10.1002/mds.21116
Google Scholar | Crossref | Medline | ISI42. Morgante, L, Epifanio, A, Spina, E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis [published correction appears in Clin Neuropharmacol. 2004 Sep-Oct;27(5):256]. Clin Neuropharmacol. 2004;27(4):153–156. doi:10.1097/01.wnf.0000136891.17006.ec
Google Scholar | Crossref | Medline | ISI43. Merims, D, Balas, M, Peretz, C, Shabtai, H, Giladi, N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6):331–337. doi:10.1097/01.WNF.0000236769.31279.19
Google Scholar | Crossref | Medline | ISI44. Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2014 Jul 5;384(9937):28]. Lancet. 2014;383(9916):533–540. doi:10.1016/S0140-6736(13)62106-6
Google Scholar | Crossref | Medline | ISI45. Seppi, K, Ray Chaudhuri, K, Coelho, M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review [published correction appears in Mov Disord. 2019 May;34(5):765]. Mov Disord. 2019;34(2):180–198. doi:10.1002/mds.27602
Google Scholar | Crossref | Medline46. NuplazidTM (pimavanserin) [prescribing Information]. San Diego, CA: ACADIA Pharmaceuticals, Inc; 2016.
Google Scholar47. Hawkins, T, Berman, BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis [published correction appears in Neurol Clin Pract. 2017 Aug;7(4):282]. Neurol Clin Pract. 2017;7(2):157–162. doi:10.1212/CPJ.0000000000000342